Plus Therapeutics, Inc. reported compliance with Nasdaq's Equity Rule as of June 30, 2025, showing stockholders’ equity of $3 million, and additionally raised over $2 million in common stock from an equity line of credit. This filing updates that the company continues to meet Nasdaq requirements as of August 14, 2025.